Sanofi sees possible $109 mln hit from injector recall

PARIS (AP) - French drug maker Sanofi says a recall of hundreds of thousands of epinephrine injectors used to treat severe allergic reactions may end up wiping 100 million euros ($109 million) off its bottom line.

Sanofi says the financial impact of recalling its Auvi-Q and Allerject injectors in the U.S. and Canada is an initial estimate, and the final amount will be accounted for in the fourth quarter. The recall, announced Wednesday, is because the injectors may not deliver the correct dose.

Sanofi on Thursday also announced third-quarter earnings, showing higher net profit and sales despite a drop in its key diabetes treatment, Lantus.

Lantus is Sanofi's top product, though sales have been declining. It's the world's third best-selling medicine, with 2014 sales of $12.4 billion, according to British research firm GlobalData.